Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
E&Y: Pharma neglects working capital
Could Big Pharma ease some of its ills if it just managed itself better? Ernst & Young says drugmakers could free up to $35 billion in working capital just by improving their management of payments and inventories. In fact, the majority of the 16 largest U.S. and European pharma firms "have a significant opportunity" to release cash to the tune of 3 percent to 7 percent of sales, or $17 to $35 billion.
We all know Big Pharma has been suffering under generic competition and pricing pressures. Companies have been cutting costs all over the globe. But, E&Y says, drugmakers haven't paid enough attention to their working capital; pharma lags other industries in working capital management. If drugmakers would just step up and start aggressively tightening payment terms, improving credit billing and collections, and so on, they could see full cash and cost benefits within 12 to 24 months, the firm says.
- see the release from E&Y
- read the story at Pharma Times
- check out the coverage at CNN Money
Related Articles:
Industry Voices: How to survive generic erosion
Globalized generics plague Big Pharma
PPRS renegotiation will cut pharma profits
Obama, McCain united against drug costs
Congress decries drug price-gouging
Sanofi CEO: Cap drug prices
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


